- Home
- NYC vs DYAI Comparison
NYC vs DYAI Comparison
Compare NYC & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- DYAI
- Stock Information
- Founded
- NYC 2013
- DYAI 1979
- Country
- NYC United States
- DYAI United States
- Employees
- NYC N/A
- DYAI N/A
- Industry
- NYC Real Estate
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NYC Finance
- DYAI Health Care
- Exchange
- NYC Nasdaq
- DYAI Nasdaq
- Market Cap
- NYC 25.5M
- DYAI 30.2M
- IPO Year
- NYC N/A
- DYAI 2004
- Fundamental
- Price
- NYC $9.60
- DYAI $0.99
- Analyst Decision
- NYC
- DYAI Strong Buy
- Analyst Count
- NYC 0
- DYAI 1
- Target Price
- NYC N/A
- DYAI $6.00
- AVG Volume (30 Days)
- NYC 3.4K
- DYAI 116.6K
- Earning Date
- NYC 11-11-2025
- DYAI 11-11-2025
- Dividend Yield
- NYC N/A
- DYAI N/A
- EPS Growth
- NYC N/A
- DYAI N/A
- EPS
- NYC N/A
- DYAI N/A
- Revenue
- NYC $54,865,000.00
- DYAI $4,135,078.00
- Revenue This Year
- NYC $8.40
- DYAI $34.23
- Revenue Next Year
- NYC $1.62
- DYAI $19.57
- P/E Ratio
- NYC N/A
- DYAI N/A
- Revenue Growth
- NYC N/A
- DYAI 129.20
- 52 Week Low
- NYC $7.89
- DYAI $0.71
- 52 Week High
- NYC $16.30
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- NYC 36.10
- DYAI 57.31
- Support Level
- NYC $9.11
- DYAI $0.94
- Resistance Level
- NYC $10.50
- DYAI $1.01
- Average True Range (ATR)
- NYC 0.77
- DYAI 0.05
- MACD
- NYC -0.05
- DYAI 0.01
- Stochastic Oscillator
- NYC 22.98
- DYAI 73.87
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.